- Home
- MRNA vs EVR Comparison
MRNA vs EVR Comparison
Compare MRNA & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- EVR
- Stock Information
- Founded
- MRNA 2010
- EVR 1995
- Country
- MRNA United States
- EVR United States
- Employees
- MRNA N/A
- EVR N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- EVR Investment Managers
- Sector
- MRNA Health Care
- EVR Finance
- Exchange
- MRNA Nasdaq
- EVR Nasdaq
- Market Cap
- MRNA 9.2B
- EVR 11.7B
- IPO Year
- MRNA 2018
- EVR 2006
- Fundamental
- Price
- MRNA $24.36
- EVR $305.27
- Analyst Decision
- MRNA Hold
- EVR Buy
- Analyst Count
- MRNA 15
- EVR 9
- Target Price
- MRNA $36.69
- EVR $320.11
- AVG Volume (30 Days)
- MRNA 11.7M
- EVR 445.5K
- Earning Date
- MRNA 11-06-2025
- EVR 10-29-2025
- Dividend Yield
- MRNA N/A
- EVR 1.10%
- EPS Growth
- MRNA N/A
- EVR 61.35
- EPS
- MRNA N/A
- EVR 12.55
- Revenue
- MRNA $2,232,000,000.00
- EVR $3,543,533,000.00
- Revenue This Year
- MRNA N/A
- EVR $24.72
- Revenue Next Year
- MRNA $10.38
- EVR $17.06
- P/E Ratio
- MRNA N/A
- EVR $24.24
- Revenue Growth
- MRNA N/A
- EVR 27.05
- 52 Week Low
- MRNA $23.04
- EVR $148.63
- 52 Week High
- MRNA $56.70
- EVR $364.42
- Technical
- Relative Strength Index (RSI)
- MRNA 43.32
- EVR 44.49
- Support Level
- MRNA $23.48
- EVR $311.88
- Resistance Level
- MRNA $25.56
- EVR $309.18
- Average True Range (ATR)
- MRNA 1.46
- EVR 10.64
- MACD
- MRNA -0.32
- EVR -0.51
- Stochastic Oscillator
- MRNA 15.89
- EVR 38.82
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About EVR Evercore Inc.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.